Abstract
// Rajasree P. Chowdry 1 , Gabriel L. Sica 2, 3 , Sungjin Kim 2, 4, 7 , Zhengjia Chen 2, 4 , Aaron Goodman 1 , Diane Alexis 2 , Xingming Deng 2, 5 , Taofeek K. Owonikoko 2, 6 1 Department of Medicine, Emory University School of Medicine Atlanta, GA, USA 2 Winship Cancer Institute of Emory University, Atlanta, GA, USA 3 Department of Pathology, Emory University, Atlanta, GA, USA 4 Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA 5 Department of Radiation Oncology, Emory University School of Medicine Atlanta, GA, USA 6 Department of Hematology and Medical, Emory University School of Medicine Atlanta, GA, USA 7 Current affiliation: Cedars-Sinai Medical Center, Los Angeles, CA, USA Correspondence to: Taofeek K. Owonikoko, e-mail: towonik@emory.edu Keywords: small cell lung cancer, carcinoid, Bcl-2, Mcl-1, survival Received: October 23, 2015 Accepted: February 09, 2016 Published: February 18, 2016 ABSTRACT Background: We hypothesized that the activated phosphorylated forms of proapoptotic Bcl-2 family of proteins is most relevant to small cell lung cancer (SCLC) biology. We therefore characterized pBcl-2 and pMcl-1 in pulmonary neuroendocrine tumors to better elucidate the role of these proteins in SCLC. Methods: We analyzed archival samples of pulmonary carcinoid, SCLC and large-cell neuroendocrine carcinoma (LCNEC) by immunohistochemistry (IHC). Association of protein expression with age, gender, smoking status, tumor type, stage and survival was assessed by Wilcoxon rank-sum test, Kruskal-Wallis test, Spearman rank correlation, and Cox regression model. Results: We employed 77 cases: carcinoid (21%), SCLC (53%) and LCNEC (26%); median age of 61.5 years, 75% Caucasians and 60% female. Carcinoid had lower median expression of Bcl-2 [0 (0 - 100) vs. 90 (0 - 300); p<0.001] and pBcl-2 [12.5 (0 - 255) vs. 190 (0 - 300); p<.001] compared to SCLC and LCNEC. On univariate analyses, high nuclear pBcl-2 expression was associated with adverse features (smoking, malignant histology, higher stage) and higher risk of progression (PFS HR: 1.45; 95% CI:1.13-1.85; p=0.004) and death (OS HR: 1.32; 95% CI: 0.99-1.75;p=0.054). High cytoplasmic Mcl-1 immunoscore was significantly associated with male gender (p-value= 0.009), and higher risk of progression (HR: 1.31 (1.02-1.68); p=0.036). On multivariable analysis, pBcl-2 remained significantly associated with PFS both by intensity (HR: 1.54; 1.08-2.20; p=0.016) and immunoscore (HR: 1.41; 0.99-2.02; p=0.058). Conclusions: pBcl-2 and pMcl-1 showed stronger correlation with adverse prognostic features in SCLC and should be considered superior biomarkers for patient selection for therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.